P3hr1

Burkitt's lymphoma (BL-2, BL-28, DAUDI, P3HR1, RAJI and RAMOS) and acute
myeloid leukemia (MV4.11 and THP.1) cell lines were purchased from ATCC (Manassas,
VA, USA). The multiple myeloma cell lines were kindly provided by Dr G. Tonon. The
Eμ-Myc lymphomas were derived from Eμ-Myc mice.^{18 (link)} Eμ-Myc lymphoma cells were cultured in
Dulbecco's Modified Eagle's Medium (DMEM) and Iscove's Modified
Dulbecco's Medium (ratio 1:1) supplemented with 10% fetal bovine
serum, 2 mml-glutamine, 1% penicillin/streptomycin,
25 μm β-mercaptoethanol, 1% non-essential
amino acids. Murine embryonic fibroblasts (MEFs) were derived from 13.5 day
post-coitum C57/BL6 or MycER knock-in embryos.^{19 (link)} Burkitt's lymphoma (BL), acute myeloid leukemia
(AML) and multiple myeloma (MM) cell lines were cultured in Roswell Park Memorial
Institute (RPMI) medium supplemented with 10% fetal bovine serum,
2 mMl-glutamine and 1% penicillin/streptomycin. MEFs were
cultures with DMEM medium supplemented with 10% fetal bovine serum,
2 mml-glutamine, 1% penicillin/streptomycin,
25 μm β-mercaptoethanol, 1% non-essential
amino acids. All the cells were grown at 37 °C and 5%
CO₂, except for MEFs that were grown at 37 °C in low
oxygen.

p53 WT cancer cells including A375, IM-9, HepG2, SKCO-1, HeLa, MCF-7, U-87-MG, LNCaP-FGC, NCI-H711, HCT116, U2OS and p53 MT cancer cells including MDA-MB-468, MOLT4, SW837, NCI-H23, P3HR1, PSN1, SKLMS1, SKLU1, SK-UT-1 and SNU-16 lines were procured from ATCC (VA, USA). HEK293T cells were procured from Cell BioLabs Inc. (San Diego, CA) and HEK293FT cells were procured by Thermo Fisher Scientific (MA, USA). Briefly, the cells were cultured in monolayer in respective growth mediums (Dulbecco's modified Eagle's medium (DMEM) or RPMI 1640) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) and antibiotics (1% penicillin/streptomycin) and incubated under normoxic conditions at 37°C in a humidified atmosphere of 95% air and 5% CO₂.